News & Events
-
Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis BEpigenic Therapeutics today announced that it has received approval of CTA from the New Zealand Medicines and Medsafe and HDEC to initiate a clinical trial for EPI-003, which is an investigational, liver-targeting antiviral therapy for CHB virus infection.
2024/11/20 -
Epigenic Therapeutics to present recent anti-HBV project update at 2024 annual conference of AASLD
Shanghai, China, 26 October 2024- Epigenic Therapeutics announced acceptance of an oral presentation at the AASLD to be held in San Diego, California, 15-19 November 2024. The presentation is entitled “Robust and sustainable elimination of HBsAg by epigenome modulation enables seroconversion of chronic HBV infection in HBV mouse model”.
2024/10/26 -
Epigenic Therapeutics Announced to be listed in“Forbes Asia 100 To Watch 2024”Shanghai, China, 29 August 2024—Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, officially announced to be listed in “Forbes Asia 100 To Watch 2024”.
2024/09/02 -
Epigenic Therapeutics to present preclinical update of company's epigenome modulation technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the LiverShanghai, China, 10 May 2024- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, announced acceptance of an oral presentation at the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, 5-8 J
2024/05/01 -
SITC-poster：Epigenetic editing as a promising strategy to enhance efficacy and genomic integrity of CAR T cell therapy2023/11/05
-
202024/112024/11/20Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis BEpigenic Therapeutics today announced that it has received approval of CTA from the New Zealand Medicines and Medsafe and HDEC to initiate a clinical trial for EPI-003, which is an investigational, liver-targeting antiviral therapy for CHB virus infection.
-
262024/102024/10/26Epigenic Therapeutics to present recent anti-HBV project update at 2024 annual conference of AASLD
Shanghai, China, 26 October 2024- Epigenic Therapeutics announced acceptance of an oral presentation at the AASLD to be held in San Diego, California, 15-19 November 2024. The presentation is entitled “Robust and sustainable elimination of HBsAg by epigenome modulation enables seroconversion of chronic HBV infection in HBV mouse model”.
-
022024/092024/09/02Epigenic Therapeutics Announced to be listed in“Forbes Asia 100 To Watch 2024”
Shanghai, China, 29 August 2024—Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, officially announced to be listed in “Forbes Asia 100 To Watch 2024”.
-
012024/052024/05/01Epigenic Therapeutics to present preclinical update of company's epigenome modulation technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the Liver
Shanghai, China, 10 May 2024- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, announced acceptance of an oral presentation at the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, 5-8 J
-
052023/112023/11/05SITC-poster：Epigenetic editing as a promising strategy to enhance efficacy and genomic integrity of CAR T cell therapy
